MOTHAFFAR RIMAWI to Ki-67 Antigen
This is a "connection" page, showing publications MOTHAFFAR RIMAWI has written about Ki-67 Antigen.
Connection Strength
0.078
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
Score: 0.055
-
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):819-27.
Score: 0.023